Page last updated: 2024-12-08

miglitol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID441314
CHEMBL ID1561
CHEBI ID6935
SCHEMBL ID22593
MeSH IDM0132575

Synonyms (95)

Synonym
BIDD:GT0732
plumarol
diastabol
glyset
sk-983
bay-m-1099
(2r,3r,4r,5s)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
MLS001424128
C07708
72432-03-2
miglitol ,
smr000466381
MLS000759514
DB00491
miglitol (jp17/usan/inn)
D00625
glyset (tn)
miglitolum [latin]
n-(2-hydroxyethyl)-1-deoxynojirimycin
3,4,5-piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2r-(2alpha,3beta,4alpha,5beta))-
einecs 276-661-6
bay m 1099
1,5-dideoxy-1,5-((2-hydroxyethyl)imino)-d-glucitol
bay 1099
n-hydroxyethyl-1-desoxynojirimycin
(2r,3r,4r,5s)-1-(2-hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol
HMS2051D05
(2r,3r,4r,5s)-1-ethoxy-2-(hydroxymethyl)piperidine-3,4,5-triol
bdbm50242271
cid_441314
nsc-758702
chebi:6935 ,
CHEMBL1561 ,
(4r,5r)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
n-(2-hydroxyethyl)moranoline
A837526
n-hydroxyethyl-1-desoxy-nojirimycin
0v5436jaqw ,
unii-0v5436jaqw
miglitol [usan:inn:ban]
miglitolum
hsdb 8022
nsc 758702
dtxsid0023323 ,
cas-72432-03-2
dtxcid703323
tox21_111436
M2302
AKOS015969689
CCG-100920
miglitol [jan]
miglitol [orange book]
miglitol [vandf]
miglitol [inn]
miglitol [usan]
3,4,5-piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2r-(2.alpha.,3.beta.,4.alpha.,5.beta.))-
miglitol [who-dd]
miglitol [mart.]
miglitol [mi]
S2589
n-hydroxylethyl-1-deoxynojirimycin
gtpl4842
AB00639982-06
HY-B0481
NC00170
SCHEMBL22593
NCGC00270540-02
tox21_111436_1
KS-1242
MLS006011963
W-104490
(2r,3r,4r,5s)-1-(2-hydroxyethyl)-2-(2-hydroxymethyl)-3,4,5-piperidinetriol
bay m1009
AB00639982_08
bay-m1099
bay1099
SR-01000759413-4
sr-01000759413
baym1099
mfcd00867240
HMS3713J07
Z1269163651
miglitol (glyset)
1204250-58-7
Q772735
BRD-K44779798-001-06-5
C76308
EN300-119541
bay o1099
3,4,5-piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2r-(2alpha,3beta,4alpha, 5beta))-
1,5-dideoxy-1,5-
miglitol (mart.)
miglitolum (latin)
n-(beta-hydroxyethyl)-1-deoxynojirimycin
n-hydroxyethyl-1-desoxynojirimycin (bay o1099)

Research Excerpts

Overview

Miglitol is an alpha-glucosidase inhibitor that exerts its effect through the delayed absorption of complex carbohydrates in the small intestine. Miglitol is a useful drug in order to improve the glycemic control in diabetic type 2 patients treated previously with other drugs.

ExcerptReferenceRelevance
"Miglitol is an alpha-glucosidase inhibitor that improves post-prandial hyperglycemia, and it is the only drug in its class that enters the bloodstream. "( Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates.
Fujita, Y; Hiraga, H; Kikuchi, O; Kim, HJ; Kitamura, T; Kitazumi, T; Kobayashi, M; Maruyama, J; Nakagawa, Y; Okamatsu-Ogura, Y; Saito, M; Sasaki, T; Shibata, H; Shimpuku, M; Susanti, VY; Yokota-Hashimoto, H, 2013
)
3.28
"Miglitol is an α-glucosidase inhibitor (AGI) used as an antihyperglycemic agent in the treatment of type 2 diabetes mellitus. "( Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
Chae, SW; Choi, HG; Im, YJ; Jang, H; Jeon, JY; Kang, S; Kim, KH; Kim, MG; Kim, Y; Lee, SY, 2014
)
2.08
"Miglitol is an absorbable alpha-glucosidase inhibitor that is used to control post-prandial hyperglycemia. "( Miglitol protects against age-dependent weight gain in mice: A potential role of increased UCP1 content in brown adipose tissue.
Hiraga, H; Kitamura, T; Sasaki, T; Yokota-Hashimoto, H, 2015
)
3.3
"Miglitol is a useful drug in order to improve the glycemic control in diabetic type 2 patients treated previously with other drugs and with insufficient control of the blood glucose. "( [Usefulness of miglitol in patients with diabetes mellitus type 2 and insufficient control of the blood glucose].
Aller, R; Conde Valentín, R; de Luis Román, DA; del Pozo García, E; Romero Bobillo, E, 2004
)
2.12
"Thus miglitol appears to be a safe and effective adjunct in the management of Type 2 DM, in association with insulin."( Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Bauer, RJ; Mitrakou, A; Raptis, AE; Raptis, SA; Schulz, H; Tountas, N, 1998
)
0.99
"Miglitol is an alpha-glucosidase inhibitor that exerts its effect through the delayed absorption of complex carbohydrates in the small intestine, resulting in a decrease in postprandial glucose concentrations that are directly correlated with the dietary carbohydrate content. "( Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
Baker, DE; Campbell, LK; Campbell, RK, 2000
)
3.19
"Miglitol is an effective and safe treatment option in patients with type 2 diabetes mellitus who are inadequately controlled with diet or oral sulfonylurea therapy. "( Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
Baker, DE; Campbell, LK; Campbell, RK, 2000
)
3.19
"Miglitol is an alpha-glucosidase inhibitor which lowers blood glucose and insulin concentrations in healthy volunteers after a starch meal. "( Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
Bopape, ML; Foukaridis, GN; Joubert, PH, 1987
)
3.16

Effects

Miglitol has an anti-anginal ischaemia effect via a mechanism that is independent of regional myocardial blood flow. Miglitol has no or a very small effect on fasting blood glucose levels.

ExcerptReferenceRelevance
"Miglitol has an anti-anginal ischaemia effect via a mechanism that is independent of regional myocardial blood flow."( The anti-diabetic drug miglitol is protective against anginal ischaemia through a mechanism independent of regional myocardial blood flow in the dog.
Arai, M; Chen, XH; Fujiwara, H; Hashimoto, K; Lu, C; Minatoguchi, S; Takemura, G; Uno, Y; Wang, N, 2005
)
1.36
"Miglitol has an anti-anginal ischaemia effect via a mechanism that is independent of regional myocardial blood flow."( The anti-diabetic drug miglitol is protective against anginal ischaemia through a mechanism independent of regional myocardial blood flow in the dog.
Arai, M; Chen, XH; Fujiwara, H; Hashimoto, K; Lu, C; Minatoguchi, S; Takemura, G; Uno, Y; Wang, N, 2005
)
1.36
"Miglitol has no or a very small effect on fasting blood glucose levels."( Miglitol, a new alpha-glucosidase inhibitor.
Huijberts, MS; Sels, JP; Wolffenbuttel, BH, 1999
)
2.47

Actions

ExcerptReferenceRelevance
"Miglitol may cause some hepatocellular, lysosomal gly"( Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II).
Creutzfeldt, W; Lamberts, R; Lembcke, B; Wöhler, J, 1991
)
1

Treatment

Miglitol treatment suppressed HFHSD-induced NASH development with the suppression of hepatic Toll-like receptor 4 expression, increased glucagon-like peptide 1 (GLP-1) concentration, and reduced lipopolysaccharide concentration in portal plasma. Miglitol-treated rats had lower nonfasting blood glucose levels and higher 1,5-anhydroglucitol levels, a marker for glucose fluctuations.

ExcerptReferenceRelevance
"Miglitol treatment suppressed HFHSD-induced NASH development with the suppression of hepatic Toll-like receptor 4 expression, increased glucagon-like peptide 1 (GLP-1) concentration, and reduced lipopolysaccharide concentration in portal plasma."( Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
Kishida, Y; Ohno, H; Oki, K; Okubo, H; Yoneda, M, 2017
)
1.58
"Miglitol-treated mice showed reduced adiposity and increased oxygen consumption compared to controls, accompanied by higher UCP1 protein abundance in brown adipose tissue."( Miglitol protects against age-dependent weight gain in mice: A potential role of increased UCP1 content in brown adipose tissue.
Hiraga, H; Kitamura, T; Sasaki, T; Yokota-Hashimoto, H, 2015
)
2.58
"Miglitol treatment may lead to increased α-glucosidase activities toward the ileum because carbohydrate flow toward the ileum increases."( Changes in α-glucosidase activities along the jejunal-ileal axis of normal rats by the α-glucosidase inhibitor miglitol.
Goda, T; Hanai, E; Kuranuki, S; Mochizuki, K; Suruga, K, 2010
)
1.29
"The miglitol treatment group showed significantly greater reductions in HbA1c and PPG levels compared with the placebo group."( Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas.
Chou, CW; Chu, CH; Hsieh, SH; Shih, KC, 2011
)
1.11
"Miglitol-treated rats had lower nonfasting blood glucose levels and higher 1,5-anhydroglucitol levels, a marker for glucose fluctuations, at week 40 than control rats."( Treatment with the α-glucosidase inhibitor miglitol from the preonset stage in Otsuka Long-Evans Tokushima Fatty rats improves glycemic control and reduces the expression of inflammatory cytokine genes in peripheral leukocytes.
Fuchigami, M; Fukaya, N; Goda, T; Mochizuki, K; Tanaka, Y, 2011
)
1.35
"2. Miglitol treatment resulted in clinical improvement toward normal in percent glycosylated hemoglobin, glycemic and insulinogenic responses to an oral glucose tolerance, and in liver glucokinase activity, in concert with modest decreases in weight gain in obese rats."( The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
DeBouno, JF; Michaelis, OE; Tulp, OL, 1993
)
1.04
"Miglitol treatment of non-insulin-requiring Hispanic NIDDM patients at doses from 50 to 200 mg t.i.d. "( Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Coniff, RF; Davidson, JA; Feig, PU; Haffner, SM; Johnston, PS; Krol, A, 1998
)
1.74
"Miglitol treatment was associated with a mean placebo-subtracted reduction in HbA1C from baseline of 1.19% at 6 months. "( Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Coniff, RF; Feig, PU; Johnston, PS; Kelley, DE; Krol, A; Mooradian, AD, 1998
)
1.74
"Miglitol treatment appears to be at least as efficacious in the African-American type 2 population as in the U.S. "( Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Coniff, RF; Feig, PU; Johnston, PS; Kelley, DE; Krol, A; Mooradian, AD, 1998
)
1.74
"Miglitol treatment may improve islet sensitivity to glucose either through effects on islet metabolism requiring prolonged exposure or by improvement in postmeal glycemia, despite persistent hyperglycemia."( Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Axen, KV; Li, X; Sclafani, A, 1999
)
2.47
"Miglitol treatment was associated with improvements in glucokinase and malic enzyme in both strains, and in improvements in glycemic parameters in obese rats."( The effects of low-dose Bay-m-1099 (Miglitol) on serum lipids and liver enzyme activity of obese and obese-diabetic corpulent rats.
DeBouno, JF; Michaelis, OE; Szepesi, B; Tulp, OL, 1991
)
1.28
"Treatment with miglitol offers the elderly type 2 diabetic patient significant reductions in daylong glycemia as measured by HbA1c."( Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Coniff, RF; Johnston, PS; Lebovitz, HE; Munera, CL; Raskin, P; Simonson, DC, 1998
)
0.64

Toxicity

Miglitol monotherapy is effective and safe in NIDDM patients. 5% patients treated with miglitol reported adverse events like flatulence, abdominal pain, nausea/vomiting, diarrhoea and dyspepsia.

ExcerptReferenceRelevance
"Miglitol monotherapy is effective and safe in NIDDM patients."( The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Berlin, C; Feig, PU; Petzinna, D; Ratzmann, KP; Rybka, J; Schernthaner, G; Segal, P, 1997
)
2.04
"5% patients treated with miglitol reported adverse events like flatulence, abdominal pain, nausea/vomiting, diarrhoea and dyspepsia."( Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
Baliga, VP; Jayaram, S; Kinagi, S; Mishra, AB; Periyandavar, I; Rajadhyaksha, GC; Sharma, A; Singh, KP, 2007
)
0.89

Pharmacokinetics

This was a double-blind, randomised, placebo-controlled, cross-over study to determine the possible pharmacodynamic and pharmacokinetic interaction of miglitol and warfarin sodium.

ExcerptReferenceRelevance
"This was a double-blind, randomised, placebo-controlled, cross-over study to determine the possible pharmacodynamic and pharmacokinetic interaction of miglitol (CAS 72432-03-2, Bay m 1099) and warfarin sodium (CAS 129-06-6) in healthy volunteers."( Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.
Duursema, L; Groenewoud, G; Hundt, HK; Middle, MV; Müller, FO; Schall, R, 1996
)
0.8
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The PK parameters including AUCt, AUC∞, Cmax, and tmax were measured and all treatment-emergent adverse events (TEAEs) and their relationships to study these medications were recorded throughout the entire study."( Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
Chae, SW; Choi, HG; Im, YJ; Jang, H; Jeon, JY; Kang, S; Kim, KH; Kim, MG; Kim, Y; Lee, SY, 2014
)
0.63
" The PK parameters including AUCt, AUC∞, Cmax, and tmax were calculated and the 90% CIs of the ratio (test/reference) of the parameters were obtained by analysis of variance (ANOVA) on logarithmically transformed data."( Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
Chae, SW; Choi, HG; Im, YJ; Jang, H; Jeon, JY; Kang, S; Kim, KH; Kim, MG; Kim, Y; Lee, SY, 2014
)
0.63
"The aim of this study was to explore the bioequivalence of miglitol based on pharmacodynamic properties."( Bioequivalence and Evaluation Parameters Based on the Pharmacodynamics of Miglitol in Healthy Volunteers.
Guo, J; Hu, XL; Li, XM; Liu, WL; Xu, PS; Xu, SM; Xu, YY; Yan, J; Zhang, YX; Zou, T, 2021
)
1.1
"To investigate the bioequivalence of miglitol orally disintegrating tablets in healthy Chinese volunteers based on pharmacodynamic (PD) and pharmacokinetic (PK) parameters."( Bioequivalence Study of Miglitol Orally Disintegrating Tablets in Healthy Chinese Volunteers Under Fasting Condition Based on Pharmacodynamic and Pharmacokinetic Parameters.
Chen, J; Dong, LC; Fan, YX; He, JC; Wu, JL; Yu, CJ; Zhang, J; Zhang, P; Zhang, XP; Zhao, MX; Zhou, MD; Zhu, FJ, 2023
)
1.49

Compound-Compound Interactions

Study investigated potential drug-drug interactions between 5 mg luseogliflozin and the following OADs usually used in Japan: 1 mg glimepiride, 250 mg metformin, 30 mg pioglitazone, 50 mg sitagliptin.

ExcerptReferenceRelevance
" We evaluated the effects of long-term treatment with vildagliptin, a DPP-4 inhibitor, on metabolic parameters and β-cell function, in combination with miglitol, an alpha-glucosidase inhibitor, in diet-controlled db/db mice."( Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Abe, H; Fujitani, Y; Hara, A; Ishibashi, K; Kanazawa, A; Kawamori, R; Komiya, K; Ogihara, T; Tamaki, M; Uchida, T; Watada, H, 2013
)
0.84
"A strategy for assessing potential drug-drug interactions (DDIs) based on a simulated intestinal concentration is described."( A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans.
Gunji, E; Jingu, S; Kinoshita, K; Mizuno-Yasuhira, A; Nakai, Y; Sakai, S; Samukawa, Y; Takahashi, T; Uchida, S; Yamaguchi, J, 2014
)
0.4
"We investigated the possibilities of drug-drug interactions between luseogliflozin, a sodium-glucose co-transporter-2 inhibitor, and oral antidiabetic drugs (OADs) in healthy Japanese males."( Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" As miglitol is well absorbed and acarbose is not, it is suggested that miglitol has a systemic hypoglycaemic effect, probably related to its close structural similarity to glucose, which warrants further investigation."( The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?
Foukaridis, GN; Joubert, PH; Venter, HL, 1990
)
1.2
" The reported great similarity in apparent first-order absorption rate constants (k) of seven structurally diverse compounds between the two species were obtained."( Similarity in the linear and non-linear oral absorption of drugs between human and rat.
Chiou, WL; Chung, SM; Jeong, HY; Ma, C; Wu, TC, 2000
)
0.31
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."( Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma.
Boosi, R; Kandikere, VN; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M; Yerramilli, A, 2006
)
0.56
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" We evaluated the comparative bioavailability and tolerability of the test and reference formulations in healthy male adult volunteers."( Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
Chae, SW; Choi, HG; Im, YJ; Jang, H; Jeon, JY; Kang, S; Kim, KH; Kim, MG; Kim, Y; Lee, SY, 2014
)
0.63
" Critical evaluation of the interaction data suggested that the absorption and bioavailability of many coadministered drugs were not meaningfully affected from a clinical perspective."( Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Babu, RJ; Dash, RP; Srinivas, NR, 2018
)
0.68
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Miglitol was found to inhibit the alpha-glucosidase enzyme for a longer duration of time. No reduction in fasting blood glucose, HbA1, plasma lipids, insulin dosage or weight was observed.

ExcerptRelevanceReference
"Thirty-six non-insulin-dependent diabetes mellitus (NIDDM) subjects were studied in a double-blind randomized study comparing treatment with a single dosage of 100 mg miglitol or placebo and a single-blind crossover comparison of three test meals in which the carbohydrate contained either 30, 50, or 70% starch, and quantities of fat and protein were kept constant."( alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Kingma, PJ; Menheere, PP; Nieuwenhuijzen Kruseman, AC; Sels, JP, 1992
)
0.76
"01) reduced by miglitol although no reduction in fasting blood glucose, HbA1, plasma lipids, insulin dosage or weight was observed."( Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
Gray, RS; Hillman, RJ; Scott, M, 1989
)
0.63
" Thus, with the dosage schedule employed, Bay-m-1099, but not Bay-o-1248, significantly reduced postprandial increments in plasma insulin."( The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers.
Gerich, JE; Heiling, V; Kennedy, FP; Miles, JM, 1987
)
0.27
" This might be due to the short duration of the treatment periods or the low dosage of the drug."( Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
Arends, J; Willms, BH, 1986
)
0.27
" Further studies should concentrate on the critical dosage which may strike a satisfactory balance between effects and side effects."( The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics.
Federlin, KF; Hillebrand, I; Laube, H; Mehlburger, L,
)
0.13
" These symptoms are usually dose dependent, mild to moderate in severity, occur at the onset of treatment, decline with time and resolve promptly on discontinuation of the drug or with dosage adjustment."( Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Scott, LJ; Spencer, CM, 2000
)
1.75
"To evaluate miglitol, a new oral alpha-glucosidase inhibitor, and discuss its pharmacology, therapeutics, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy."( Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
Baker, DE; Campbell, LK; Campbell, RK, 2000
)
2.13
" The aims of this study were (i) to design a controlled release (CR) mucoadhesive (in the intestine) formulation of miglitol which would inhibit the alpha-glucosidase enzyme for a longer duration of time (in comparison to the non-controlled release (IR) formulation) thus reducing the dosing frequency, and also controlling the postprandial glucose levels more effectively over a longer period of time; (ii) to assess the effect of different formulation parameters on the release of miglitol in vitro from the CR pellets; (iii) to evaluate the mucoadhesion of pellets in the intestine ex vivo; (iv) to study the effect of formulation parameters on plasma GLP-1 levels; and (v) to find out the effect of formulations on postprandial glucose levels."( Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Babu, RK; Deshpande, MC; Trivedi, RK; Venkateswarlu, V, 2009
)
0.79
" We performed in this study sucrose loading to rats with moderate postprandial hyperglycemia with/without once-daily dosing of the α-glucosidase inhibitor, miglitol, for 4 days under 4-h fasting conditions."( Reduced expression of β2 integrin genes in rat peripheral leukocytes by inhibiting postprandial hyperglycemia.
Fukaya, N; Goda, T; Mochizuki, K; Shimada, M; Tanaka, Y, 2010
)
0.56
" Although the daily insulin dosage and the glucose level before meals did not differ between the two groups, the 1-h postprandial glucose level after each meal, 2-h glucose level after lunch and dinner, mean and standard deviation of glucose, and amplitude of glucose excursion were significantly lower or smaller in the MDI plus miglitol group than in the MDI group."( Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
Fukuda, H; Fuse, J; Ishii, S; Katabami, T; Kato, H; Kobayashi, H; Kobayashi, S; Kondo, A; Nagai, Y; Ohmori, S; Ohta, A; Sada, Y; Tanaka, Y, 2012
)
0.82
" Hence, dosage adjustment is not warranted in the use of AGIs in T2DM patients in situations of comorbidity."( Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Babu, RJ; Dash, RP; Srinivas, NR, 2018
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.49150.001530.607315,848.9004AID1224841; AID1224842
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency2.89340.036619.637650.1187AID1466; AID2100; AID2112; AID2242
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.54813.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.54813.548118.039535.4813AID1466
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency8.91250.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Trehalase Sus scrofa (pig)IC50 (µMol)700.00002.50002.50002.5000AID338569
type-1 angiotensin II receptorHomo sapiens (human)IC50 (µMol)40.00002.22108.230418.7980AID463214
apelin receptorHomo sapiens (human)IC50 (µMol)31.70001.75003.39008.3500AID2784
Lysosomal alpha-mannosidaseHomo sapiens (human)IC50 (µMol)379.00000.01000.03000.0500AID1168529
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Maltase-glucoamylase, intestinalHomo sapiens (human)IC50 (µMol)4.46670.04003.46529.0000AID1306873; AID1684763; AID466668
Maltase-glucoamylase, intestinalHomo sapiens (human)Ki1.00000.17001.86737.3000AID536212
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Lysosomal acid glucosylceramidaseHomo sapiens (human)IC50 (µMol)84.00000.03002.35898.8000AID342801
Lysosomal alpha-glucosidaseHomo sapiens (human)IC50 (µMol)1.11670.06002.28897.8000AID342799; AID342811; AID466672
Sucrase-isomaltase, intestinalHomo sapiens (human)IC50 (µMol)0.50000.04902.72947.8000AID466667
Sucrase-isomaltase, intestinalRattus norvegicus (Norway rat)IC50 (µMol)12.63400.04001.848310.0000AID1181387; AID1181388; AID1306871; AID1306872; AID342795; AID342797; AID550395; AID550397; AID711102; AID711103
Glycogen debranching enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)0.39000.11000.69752.1000AID342805
Oligo-1,6-glucosidase IMA1Saccharomyces cerevisiae S288CIC50 (µMol)9,900.00009.37009.37009.3700AID441055
Ceramide glucosyltransferaseHomo sapiens (human)IC50 (µMol)1,000.00000.09000.13250.2000AID466666
Beta-galactosidaseBos taurus (cattle)IC50 (µMol)200.00001.50002.70003.6000AID1251294
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)IC50 (µMol)1.12250.08002.50619.8500AID1181386; AID342793; AID550393; AID711104
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)Ki0.46000.00871.09573.5000AID710939
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (134)

Processvia Protein(s)Taxonomy
mannose metabolic processLysosomal alpha-mannosidaseHomo sapiens (human)
protein deglycosylationLysosomal alpha-mannosidaseHomo sapiens (human)
learning or memoryLysosomal alpha-mannosidaseHomo sapiens (human)
oligosaccharide catabolic processLysosomal alpha-mannosidaseHomo sapiens (human)
protein modification processLysosomal alpha-mannosidaseHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
mitochondrion organizationLysosomal acid glucosylceramidaseHomo sapiens (human)
neuron projection developmentLysosomal acid glucosylceramidaseHomo sapiens (human)
glucosylceramide catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
autophagyLysosomal acid glucosylceramidaseHomo sapiens (human)
lysosome organizationLysosomal acid glucosylceramidaseHomo sapiens (human)
cholesterol metabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
determination of adult lifespanLysosomal acid glucosylceramidaseHomo sapiens (human)
cellular response to starvationLysosomal acid glucosylceramidaseHomo sapiens (human)
response to pHLysosomal acid glucosylceramidaseHomo sapiens (human)
microglia differentiationLysosomal acid glucosylceramidaseHomo sapiens (human)
regulation of macroautophagyLysosomal acid glucosylceramidaseHomo sapiens (human)
antigen processing and presentationLysosomal acid glucosylceramidaseHomo sapiens (human)
lipid storageLysosomal acid glucosylceramidaseHomo sapiens (human)
cerebellar Purkinje cell layer formationLysosomal acid glucosylceramidaseHomo sapiens (human)
pyramidal neuron differentiationLysosomal acid glucosylceramidaseHomo sapiens (human)
respiratory electron transport chainLysosomal acid glucosylceramidaseHomo sapiens (human)
termination of signal transductionLysosomal acid glucosylceramidaseHomo sapiens (human)
lipid glycosylationLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of protein-containing complex assemblyLysosomal acid glucosylceramidaseHomo sapiens (human)
regulation of TOR signalingLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of interleukin-6 productionLysosomal acid glucosylceramidaseHomo sapiens (human)
T cell differentiation in thymusLysosomal acid glucosylceramidaseHomo sapiens (human)
response to testosteroneLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of protein dephosphorylationLysosomal acid glucosylceramidaseHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of protein-containing complex disassemblyLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of MAP kinase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of neuron apoptotic processLysosomal acid glucosylceramidaseHomo sapiens (human)
response to estrogenLysosomal acid glucosylceramidaseHomo sapiens (human)
sphingosine biosynthetic processLysosomal acid glucosylceramidaseHomo sapiens (human)
ceramide biosynthetic processLysosomal acid glucosylceramidaseHomo sapiens (human)
cell maturationLysosomal acid glucosylceramidaseHomo sapiens (human)
brain morphogenesisLysosomal acid glucosylceramidaseHomo sapiens (human)
homeostasis of number of cellsLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of inflammatory responseLysosomal acid glucosylceramidaseHomo sapiens (human)
neuromuscular processLysosomal acid glucosylceramidaseHomo sapiens (human)
neuron apoptotic processLysosomal acid glucosylceramidaseHomo sapiens (human)
establishment of skin barrierLysosomal acid glucosylceramidaseHomo sapiens (human)
microglial cell proliferationLysosomal acid glucosylceramidaseHomo sapiens (human)
motor behaviorLysosomal acid glucosylceramidaseHomo sapiens (human)
cellular response to tumor necrosis factorLysosomal acid glucosylceramidaseHomo sapiens (human)
hematopoietic stem cell proliferationLysosomal acid glucosylceramidaseHomo sapiens (human)
response to dexamethasoneLysosomal acid glucosylceramidaseHomo sapiens (human)
lymphocyte migrationLysosomal acid glucosylceramidaseHomo sapiens (human)
response to thyroid hormoneLysosomal acid glucosylceramidaseHomo sapiens (human)
beta-glucoside catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of protein lipidationLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of neuronal action potentialLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of autophagy of mitochondrion in response to mitochondrial depolarizationLysosomal acid glucosylceramidaseHomo sapiens (human)
autophagosome organizationLysosomal acid glucosylceramidaseHomo sapiens (human)
regulation of lysosomal protein catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
lactose catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
glycosylceramide catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
quercetin catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
cellobiose catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
maltose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
regulation of the force of heart contractionLysosomal alpha-glucosidaseHomo sapiens (human)
diaphragm contractionLysosomal alpha-glucosidaseHomo sapiens (human)
heart morphogenesisLysosomal alpha-glucosidaseHomo sapiens (human)
glycogen catabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
glucose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
lysosome organizationLysosomal alpha-glucosidaseHomo sapiens (human)
locomotory behaviorLysosomal alpha-glucosidaseHomo sapiens (human)
tissue developmentLysosomal alpha-glucosidaseHomo sapiens (human)
aorta developmentLysosomal alpha-glucosidaseHomo sapiens (human)
vacuolar sequesteringLysosomal alpha-glucosidaseHomo sapiens (human)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling postureLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseHomo sapiens (human)
cardiac muscle contractionLysosomal alpha-glucosidaseHomo sapiens (human)
glycophagyLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose catabolic processSucrase-isomaltase, intestinalHomo sapiens (human)
polysaccharide digestionSucrase-isomaltase, intestinalHomo sapiens (human)
protein lipidationCeramide glucosyltransferaseHomo sapiens (human)
glucosylceramide biosynthetic processCeramide glucosyltransferaseHomo sapiens (human)
glycosphingolipid biosynthetic processCeramide glucosyltransferaseHomo sapiens (human)
epidermis developmentCeramide glucosyltransferaseHomo sapiens (human)
regulation of signal transductionCeramide glucosyltransferaseHomo sapiens (human)
cell differentiationCeramide glucosyltransferaseHomo sapiens (human)
keratinocyte differentiationCeramide glucosyltransferaseHomo sapiens (human)
leptin-mediated signaling pathwayCeramide glucosyltransferaseHomo sapiens (human)
neuron developmentCeramide glucosyltransferaseHomo sapiens (human)
establishment of skin barrierCeramide glucosyltransferaseHomo sapiens (human)
intestinal lipid absorptionCeramide glucosyltransferaseHomo sapiens (human)
cornified envelope assemblyCeramide glucosyltransferaseHomo sapiens (human)
carbohydrate metabolic processBeta-galactosidaseBos taurus (cattle)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (50)

Processvia Protein(s)Taxonomy
carbohydrate bindingLysosomal alpha-mannosidaseHomo sapiens (human)
metal ion bindingLysosomal alpha-mannosidaseHomo sapiens (human)
alpha-mannosidase activityLysosomal alpha-mannosidaseHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
galactosylceramidase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
glucosylceramidase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
signaling receptor bindingLysosomal acid glucosylceramidaseHomo sapiens (human)
scavenger receptor bindingLysosomal acid glucosylceramidaseHomo sapiens (human)
protein bindingLysosomal acid glucosylceramidaseHomo sapiens (human)
glucosyltransferase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
steryl-beta-glucosidase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
lactase activityLactase-phlorizin hydrolaseHomo sapiens (human)
galactosylceramidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
glucosylceramidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
beta-glucosidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
glycosylceramidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
protein homodimerization activityLactase-phlorizin hydrolaseHomo sapiens (human)
cellobiose glucosidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
phlorizin hydrolase activityLactase-phlorizin hydrolaseHomo sapiens (human)
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
carbohydrate bindingLysosomal alpha-glucosidaseHomo sapiens (human)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
oligo-1,6-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
sucrose alpha-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
protein bindingSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate bindingSucrase-isomaltase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
protein bindingCeramide glucosyltransferaseHomo sapiens (human)
ceramide glucosyltransferase activityCeramide glucosyltransferaseHomo sapiens (human)
dihydroceramide glucosyltransferase activityCeramide glucosyltransferaseHomo sapiens (human)
beta-galactosidase activityBeta-galactosidaseBos taurus (cattle)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
extracellular regionLysosomal alpha-mannosidaseHomo sapiens (human)
extracellular spaceLysosomal alpha-mannosidaseHomo sapiens (human)
nucleoplasmLysosomal alpha-mannosidaseHomo sapiens (human)
azurophil granule lumenLysosomal alpha-mannosidaseHomo sapiens (human)
lysosomal lumenLysosomal alpha-mannosidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal alpha-mannosidaseHomo sapiens (human)
extracellular exosomeLysosomal alpha-mannosidaseHomo sapiens (human)
lysosomeLysosomal alpha-mannosidaseHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
lysosomeLysosomal acid glucosylceramidaseHomo sapiens (human)
lysosomal membraneLysosomal acid glucosylceramidaseHomo sapiens (human)
endoplasmic reticulumLysosomal acid glucosylceramidaseHomo sapiens (human)
Golgi apparatusLysosomal acid glucosylceramidaseHomo sapiens (human)
trans-Golgi networkLysosomal acid glucosylceramidaseHomo sapiens (human)
lysosomal lumenLysosomal acid glucosylceramidaseHomo sapiens (human)
extracellular exosomeLysosomal acid glucosylceramidaseHomo sapiens (human)
plasma membraneLactase-phlorizin hydrolaseHomo sapiens (human)
external side of apical plasma membraneLactase-phlorizin hydrolaseHomo sapiens (human)
lysosomeLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseHomo sapiens (human)
plasma membraneLysosomal alpha-glucosidaseHomo sapiens (human)
membraneLysosomal alpha-glucosidaseHomo sapiens (human)
azurophil granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal lumenLysosomal alpha-glucosidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal alpha-glucosidaseHomo sapiens (human)
extracellular exosomeLysosomal alpha-glucosidaseHomo sapiens (human)
tertiary granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
ficolin-1-rich granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
autolysosome lumenLysosomal alpha-glucosidaseHomo sapiens (human)
Golgi apparatusSucrase-isomaltase, intestinalHomo sapiens (human)
plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
brush borderSucrase-isomaltase, intestinalHomo sapiens (human)
apical plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
extracellular exosomeSucrase-isomaltase, intestinalHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
Golgi membraneCeramide glucosyltransferaseHomo sapiens (human)
membraneCeramide glucosyltransferaseHomo sapiens (human)
lysosomeBeta-galactosidaseBos taurus (cattle)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (188)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1461920Inhibition of rice alpha-glucosidase pre-incubated for 1 hr followed by p-nitrophenyl-alpha-D-glucopyranoside substrate addition by fluorescence detection based assay
AID1854747Hypoglycemic activity in C57BL/6J mouse assessed as reduction in postprandial blood glucose level at 1 mg/kg measured after 30 mins by maltose tolerance test2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID342805Inhibition of rabbit muscle amylo-1,6-glucosidase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID710942Antihyperglycemic activity in overnight fasted ddY mouse assessed as decrease in blood glucose level administered via stomach tube after 60 mins by sucrose loading test relative to control2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1366740Inhibition of Canavalia ensiformis alpha-mannosidase using p-nitrophenyl-alpha-D-mannopyranoside as substrate preincubated for 1 hr followed by substrate addition measured after 10 mins by spectrophotometric method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Polyhydroxylated azetidine iminosugars: Synthesis, glycosidase inhibitory activity and molecular docking studies.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID710946Antihyperglycemic activity in overnight fasted ddY mouse assessed as decrease in blood glucose level at 3 to 5 mg/kg administered via stomach tube measured at 15 to 30 mins by maltose loading test relative to control2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1181386Inhibition of Wistar rat intestinal maltase assessed as inhibition of D-glucose release after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of α-1-C-4'-arylbutyl-L-arabinoiminofuranoses, a new class of α-glucosidase inhibitors.
AID1251292Inhibition of bovine liver beta-glucosidase using 10 mM p-nitrophenyl-alpha-D-glucopyranoside as substrate2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Quaternary Indolizidine and Indolizidone Iminosugars as Potential Immunostimulating and Glycosidase Inhibitory Agents: Synthesis, Conformational Analysis, Biological Activity, and Molecular Docking Study.
AID710940Antihyperglycemic activity in overnight fasted ddY mouse assessed as decrease in blood glucose level at 5 mg/kg administered via stomach tube after 60 mins by sucrose loading test relative to control2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID1461926Inhibition of almond beta-glucosidase at 1 mM pre-incubated for 1 hr followed by p-nitrophenyl-beta-D-glucopyranoside, substrate addition by fluorescence detection based assay
AID710938Inhibition of rat N-terminal maltase-glucoamylase catalytic domain2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID342797Inhibition of rat intestinal brush border membrane sucrase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID466668Inhibition of maltase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1334871Inhibition of rice alpha-glucosidase assessed as reduction in production of D-glucose using disaccharides as substrate incubated for 10 to 30 mins2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis and characterization of novel, conjugated, fluorescent DNJ derivatives for α-glucosidase recognition.
AID1807030Inhibition of almond beta-glucosidase2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID1807045Hypoglycemic effect in maltose treated mouse C57BL-6J assessed as reduction in postprandial blood glucose level at 1 mg/kg, po measured after 30 mins2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID1334875Inhibition of rat small intestinal brush border membrane cellobiase assessed as reduction in production of D-glucose using disaccharides as substrate incubated for 10 to 30 mins2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis and characterization of novel, conjugated, fluorescent DNJ derivatives for α-glucosidase recognition.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1807027Inhibition of green coffee beans alpha-galactosidase2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID1334872Inhibition of rat small intestinal brush border membrane maltase assessed as reduction in production of D-glucose using maltose as substrate incubated for 10 to 30 mins2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis and characterization of novel, conjugated, fluorescent DNJ derivatives for α-glucosidase recognition.
AID1366738Inhibition of Aspergillus niger alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 1 hr followed by substrate addition measured after 10 mins by spectrophotometric method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Polyhydroxylated azetidine iminosugars: Synthesis, glycosidase inhibitory activity and molecular docking studies.
AID1854736Inhibition of jack bean alpha-mannosidase2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID1807025Inhibition of jack bean alpha-mannosidase2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID1807046Hypoglycemic effect in maltose treated C57BL-6J mouse assessed as reduction in postprandial blood glucose level at 2 mg/kg, po measured after 30 mins2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID1168528Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-D-glucopyranoside substrate incubated for 10 mins by UV spectrophotometry2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
γ-Hydroxyethyl piperidine iminosugar and N-alkylated derivatives: a study of their activity as glycosidase inhibitors and as immunosuppressive agents.
AID342795Inhibition of rat intestinal brush border membrane isomaltase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID1366742Inhibition of Escherichia coli alpha-galactosidase at 1 mM using p-nitrophenyl-alpha-D-galactopyranoside as substrate preincubated for 1 hr followed by substrate addition measured after 10 mins by spectrophotometric method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Polyhydroxylated azetidine iminosugars: Synthesis, glycosidase inhibitory activity and molecular docking studies.
AID620765Selectivity ratio of Ki for human ntMGAM to Ki for mouse ctMGAM-N22011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1251291Inhibition of rice alpha-glucosidase using 10 mM p-nitrophenyl-alpha-D-glucopyranoside as substrate2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Quaternary Indolizidine and Indolizidone Iminosugars as Potential Immunostimulating and Glycosidase Inhibitory Agents: Synthesis, Conformational Analysis, Biological Activity, and Molecular Docking Study.
AID620768Selectivity ratio of Ki for human ntMGAM to Ki for mouse ctMGAM-N202011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID342793Inhibition of rat intestinal brush border membrane maltase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID1461931Inhibition of Escherichia coli beta-galactosidase at 1 mM pre-incubated for 1 hr followed by p-nitrophenyl-beta-D-galactopyranoside substrate addition by fluorescence detection based assay
AID620763Inhibition of mouse his-tagged ctSI expressed in Sf9 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1807043Hypoglycemic effect in maltose treated mouse C57BL-6J assessed as reduction in postprandial blood glucose level at 2 mg/kg, po measured after 15 mins2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID466666Inhibition of GCS by cell-based assay2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1251298Inhibition of jack bean alpha-mannosidase at 1 mM using 10 mM p-nitrophenyl-alpha-D-mannopyranoside as substrate2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Quaternary Indolizidine and Indolizidone Iminosugars as Potential Immunostimulating and Glycosidase Inhibitory Agents: Synthesis, Conformational Analysis, Biological Activity, and Molecular Docking Study.
AID1854734Inhibition of Aspergillus niger alpha-glucosidase by Lineweaver-Burk plot analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID466669Inhibition of lactase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1854743Hypoglycemic activity in C57BL/6J mouse assessed as reduction in postprandial blood glucose level at 0.5 mg/kg measured after 15 mins by maltose tolerance test2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID1807026Inhibition of Helix pomatia beta-mannosidase2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID338569Inhibition of pig kidney trehalase assessed as p-nitrophenol release by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID466855Antidiabetic activity in obese, insulin resistant C57BL/6J mouse assessed as insulin resistance at 100 mg/kg/day for 4 weeks by HOMA-IR analysis2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID466853Antidiabetic activity in obese, insulin resistant C57BL/6J mouse assessed as reduction in blood insulin at 100 mg/kg/day for 4 weeks2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1251294Inhibition of bovine liver beta-galactosidase using 10 mM p-nitrophenyl-beta-D-galactopyranoside as substrate2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Quaternary Indolizidine and Indolizidone Iminosugars as Potential Immunostimulating and Glycosidase Inhibitory Agents: Synthesis, Conformational Analysis, Biological Activity, and Molecular Docking Study.
AID1181387Inhibition of Wistar rat intestinal isomaltase assessed as inhibition of D-glucose release after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of α-1-C-4'-arylbutyl-L-arabinoiminofuranoses, a new class of α-glucosidase inhibitors.
AID1807042Hypoglycemic effect in maltose treated mouse C57BL-6J assessed as reduction in postprandial blood glucose level at 1 mg/kg, po measured after 15 mins2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1306870Inhibition of rat small intestinal maltase using maltose as substrate incubated for 30 mins by glucose-oxidase method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Hydrophobic substituents increase the potency of salacinol, a potent α-glucosidase inhibitor from Ayurvedic traditional medicine 'Salacia'.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1306873Inhibition of human small intestine microsomal maltase using maltose as substrate incubated for 30 mins by glucose-oxidase method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Hydrophobic substituents increase the potency of salacinol, a potent α-glucosidase inhibitor from Ayurvedic traditional medicine 'Salacia'.
AID711103Inhibition of rat intestinal isomaltase using isomaltase as substrate2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID620762Inhibition of human ntMGAM expressed in Drosophila S2 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1684763Inhibition of human intestinal maltase using maltose as substrate incubated for 30 mins and immediately heated for 2 mins by glucose oxidase method2021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine "Salacia," against human intestinal maltase.
AID1854740Hypoglycemic activity in C57BL/6J mouse assessed as postprandial blood glucose level at 0.5 mg/kg measured after 30 mins by maltose tolerance test (Rvb = 368.49 +/-31.28 mg/dl)2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID1854741Hypoglycemic activity in C57BL/6J mouse assessed as postprandial blood glucose level at 1 mg/kg measured after 30 mins by maltose tolerance test (Rvb = 368.49 +/-31.28 mg/dl)2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID620760Inhibition of mouse his-tagged ctMGAM-N2 expressed in Sf9 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1467130Inhibition of alpha glucosidase (unknown origin) using PNPG as substrate preincubated for 15 to 20 mins followed by substrate addition measured after 45 to 60 mins by spectrophotometric method2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and α-glucosidase inhibition activity of dihydroxy pyrrolidines.
AID620761Inhibition of mouse his-tagged ctMGAM-N20 expressed in Sf9 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID711104Inhibition of rat intestinal maltase using moltose as substrate2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID550398Inhibition of Wistar rat small intestine cellobiase at 1000 uM after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID466667Inhibition of sucrase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1383590Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 15 to 20 mins followed by substrate addition measured after 45 to 60 mins by spectrophotometric analysis2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis, molecular modeling and evaluation of α-glucosidase inhibition activity of 3,4-dihydroxy piperidines.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID710945Antihyperglycemic activity in overnight fasted ddY mouse assessed as decrease in blood glucose level at 3 to 5 mg/kg administered via stomach tube measured at 60 to 120 mins by maltose loading test relative to control2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID1854744Hypoglycemic activity in C57BL/6J mouse assessed as reduction in postprandial blood glucose level at 1 mg/kg measured after 15 mins by maltose tolerance test2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID1854735Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 1 mM2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID441055Inhibition of baker's yeast alpha-glucosidase by 4-nitrophenolate-based assay2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Amplification of the inhibitory activity of miglitol by monofluorination.
AID1854748Hypoglycemic activity in C57BL/6J mouse assessed as reduction in postprandial blood glucose level at 2 mg/kg measured after 30 mins by maltose tolerance test2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID1854738Inhibition of alpha-glucosidase in Kunming mouse using p-nitrophenyl-alpha-glycopyranoside as substrate at 1 mM2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID711102Inhibition of rat intestinal sucrase using sucrose as substrate2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID620764Inhibition of human ntSI expressed in Drosophila S2 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1168530Inhibition of alpha-galactosidase (unknown origin) using p-nitrophenyl-alpha-D-galactopyranoside substrate incubated for 10 mins by UV spectrophotometry2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
γ-Hydroxyethyl piperidine iminosugar and N-alkylated derivatives: a study of their activity as glycosidase inhibitors and as immunosuppressive agents.
AID1306871Inhibition of rat small intestinal sucrase using sucrose as substrate incubated for 30 mins by glucose-oxidase method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Hydrophobic substituents increase the potency of salacinol, a potent α-glucosidase inhibitor from Ayurvedic traditional medicine 'Salacia'.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1854733Inhibition of rice alpha-glucosidase by Lineweaver-Burk plot analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID620771Selectivity ratio of Ki for human ntMGAM to Ki for mouse ctSI2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1854745Hypoglycemic activity in C57BL/6J mouse assessed as reduction in postprandial blood glucose level at 2 mg/kg measured after 15 mins by maltose tolerance test2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID342811Inhibition of maltase in human Caco-2 cell model system after 2 hrs2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID466670Inhibition of GBA1 by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1251297Inhibition of aspergillus niger alpha-galactosidase at 1 mM using 10 mM p-nitrophenyl-alpha-D-galactopyranoside as substrate2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Quaternary Indolizidine and Indolizidone Iminosugars as Potential Immunostimulating and Glycosidase Inhibitory Agents: Synthesis, Conformational Analysis, Biological Activity, and Molecular Docking Study.
AID466856Antidiabetic activity in obese, insulin resistant C57BL/6J mouse assessed as reduction in HbA1c at 100 mg/kg/day for 4 weeks2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1854737Inhibition of almond beta-glucosidase at 1 mM2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID710939Competitive inhibition of rat intestinal maltase by Lineweaver-Burk plot analysis2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID1566362Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate incubated with substrate for 5 mins followed by enzyme addition and measured after 15 mins by spectrophotometry2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis, in vitro, and in silico studies of novel diarylimidazole-1,2,3-triazole hybrids as potent α-glucosidase inhibitors.
AID338564Inhibition of yeast maltase alpha-glucosidase assessed as p-nitrophenol release at 1000 uM by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1168529Inhibition of alpha-mannosidase (unknown origin) using p-nitrophenyl-alpha-D-mannopyranoside substrate incubated for 10 mins by UV spectrophotometry2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
γ-Hydroxyethyl piperidine iminosugar and N-alkylated derivatives: a study of their activity as glycosidase inhibitors and as immunosuppressive agents.
AID550397Inhibition of Wistar rat small intestine sucrase after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID550395Inhibition of Wistar rat small intestine isomaltase after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID466672Inhibition of lysosomal alpha-glucosidase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID550399Inhibition of Wistar rat small intestine lactase at 1000 uM after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID1854746Hypoglycemic activity in C57BL/6J mouse assessed as reduction in postprandial blood glucose level at 0.5 mg/kg measured after 30 mins by maltose tolerance test2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID342801Inhibition of human lysosomal beta-glucosidase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1461923Inhibition of yeast alpha-glucosidase at 1 mM pre-incubated for 1 hr followed by p-nitrophenyl-alpha-D-glucopyranoside substrate addition by fluorescence detection based assay
AID550393Inhibition of Wistar rat small intestine maltase after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID620826Selectivity ratio of Ki for human ntMGAM to Ki for human ntSI2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID338565Inhibition of yeast isomaltase alpha-glucosidase assessed as p-nitrophenol release at 1000 uM by spectrophotometrically2002Journal of natural products, Feb, Volume: 65, Issue:2
New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii.
AID1416275Inhibition of baker's yeast alpha-glucosidase preincubated for 15 to 20 mins followed by p-nitrophenyl-alpha-D-glucopyranoside substrate addition measured after 45 to 60 mins by spectrophotometric method2017MedChemComm, Aug-01, Volume: 8, Issue:8
Synthesis, molecular modeling and biological evaluation of aza-flavanones as α-glucosidase inhibitors.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1463974Inhibition of recombinant alpha-glucosidase (unknown origin) using PNP-G as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by spectrophotometric analysis2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.
AID342799Inhibition of human lysosomal alpha-glucosidase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID1463973Inhibition of wild type recombinant EGFR (unknown origin) by ELISA2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1807028Inhibition of Escherichia coli beta-galactosidase2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID342804Inhibition of rabbit glycogen phosphorylase B at 400 uM2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID1463975Inhibition of wild type recombinant EGFR (unknown origin) at 50 nM by ELISA relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.
AID710941Antihyperglycemic activity in overnight fasted ddY mouse assessed as decrease in blood glucose level at 2.5 mg/kg administered via stomach tube after 60 mins by sucrose loading test relative to control2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID1461932Inhibition of jack beans alpha-mannosidase beta-galactosidase at 1 mM pre-incubated for 1 hr followed by p-nitrophenyl-beta-D-galactopyranoside substrate addition by fluorescence detection based assay
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1854742Hypoglycemic activity in C57BL/6J mouse assessed as postprandial blood glucose level at 2 mg/kg measured after 30 mins by maltose tolerance test (Rvb = 368.49 +/-31.28 mg/dl)2022European journal of medicinal chemistry, Nov-05, Volume: 241Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates.
AID710949Inhibition of alpha-glucosidase in human HepG2 cells assessed as increase in expression of immature high mannose type N-linked oligosachcharides at 500 uM after 48 hrs by MALDI-TOF MS analysis relative to untreated control2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID1461928Inhibition of coffee beans alpha-galactosidase at 1 mM pre-incubated for 1 hr followed by p-nitrophenyl-alpha-D-galactopyranoside substrate addition by fluorescence detection based assay
AID1366737Inhibition of Aspergillus niger amyloglucosidase using starch as substrate after 10 mins by Miller method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Polyhydroxylated azetidine iminosugars: Synthesis, glycosidase inhibitory activity and molecular docking studies.
AID1807029Inhibition of Aspergillus niger alpha-glucosidase2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide-deoxynojirimycin Conjugates.
AID536212Inhibition of human recombinant N-terminal subunit of maltase-glucoamylase after 60 mins by glucose oxidase assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membered ring nitrogen analogue of kotalanol and its de-O-sulfonated derivative.
AID1334876Inhibition of almond beta-glucosidase assessed as reduction in production of D-glucose using disaccharides as substrate incubated for 10 to 30 mins2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis and characterization of novel, conjugated, fluorescent DNJ derivatives for α-glucosidase recognition.
AID1306872Inhibition of rat small intestinal isomaltase using isomaltose as substrate incubated for 30 mins by glucose-oxidase method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Hydrophobic substituents increase the potency of salacinol, a potent α-glucosidase inhibitor from Ayurvedic traditional medicine 'Salacia'.
AID1181388Inhibition of Wistar rat intestinal sucrase assessed as inhibition of D-glucose release after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of α-1-C-4'-arylbutyl-L-arabinoiminofuranoses, a new class of α-glucosidase inhibitors.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346029Human glucosidase alpha, acid (3.2.1.- Glycosidases)2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID1346096Human maltase-glucoamylase (3.2.1.- Glycosidases)2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membered ring nitrogen analogue of kotalanol and its de-O-sulfonated derivative.
AID1346070Mouse maltase-glucoamylase (3.2.1.- Glycosidases)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (264)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (11.74)18.7374
1990's46 (17.42)18.2507
2000's54 (20.45)29.6817
2010's110 (41.67)24.3611
2020's23 (8.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.54 (24.57)
Research Supply Index5.88 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index97.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (58.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials88 (32.71%)5.53%
Reviews29 (10.78%)6.00%
Case Studies6 (2.23%)4.05%
Observational0 (0.00%)0.25%
Other146 (54.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol. [NCT01099839]Phase 130 participants (Actual)Interventional2010-02-28Completed
Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study [NCT02456428]1,499,650 participants (Actual)Observational2014-03-31Completed
The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes [NCT02476760]1,417,914 participants (Actual)Observational2014-03-31Completed
[NCT00334399]Phase 30 participants InterventionalCompleted
Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination With an α-Glucosidase Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glyce [NCT01242202]Phase 3113 participants (Actual)Interventional2010-10-21Completed
[NCT00213122]Phase 30 participants InterventionalCompleted
[NCT00213070]Phase 30 participants InterventionalCompleted
[NCT00213109]Phase 30 participants InterventionalCompleted
[NCT00334503]Phase 30 participants InterventionalCompleted
[NCT00380822]Phase 30 participants InterventionalCompleted
The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes [NCT02475499]886,172 participants (Actual)Observational2014-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]